Biotech | January 11, 2022
Immune Biosolutions lead immunotherapy product neutralises Covid-19
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
